Critical evaluation of latanoprostene bunod in the treatment of glaucoma.

Article Details

Citation
Copy to clipboard

Garcia GA, Ngai P, Mosaed S, Lin KY

Critical evaluation of latanoprostene bunod in the treatment of glaucoma.

Clin Ophthalmol. 2016 Oct 18;10:2035-2050. eCollection 2016.

PubMed ID
27799730 [ View in PubMed
]
Abstract

Latanoprostene bunod (LBN) is a novel nitric oxide-donating prostaglandin F2alpha receptor agonist in clinical development for intraocular pressure lowering in open-angle glaucoma and ocular hypertension. Currently in Phase III clinical trials in the USA, European Union, and Japan, LBN has demonstrated promising efficacy while maintaining safety and tolerability. We review preclinical and clinical developmental efforts and evaluate the potential role of LBN monotherapy in the management of open-angle glaucoma and ocular hypertension. The current LBN clinical development program comprises eight trials, four of which have resulted in publication of complete methodology and outcomes. We additionally pool adverse events data to determine incidences across three pivotal studies. Evidence thus far indicates that LBN may be a safe and effective ocular hypotensive agent, although the potential neuroprotective effects and the impact on visual field loss remain to be evaluated.

DrugBank Data that Cites this Article

Drugs